Proteoglycans (PGs), besides their structural contribution, have emerged as dynamic components that mediate a multitude of cellular events. The various roles of PGs are attributed to their structure, spatial localization, and ability to act as ligands and receptors. Reactive oxygen species (ROS) are small mediators that are generated in physiological and pathological conditions. Besides their reactivity and ability to induce oxidative stress, a growing body of data suggests that ROS signaling is more relevant than direct radical damage in development of human pathologies.
Recent Advances:
Cell surface transmembrane PGs (syndecans, cluster of differentiation 44) represent receptors in diverse and complex transduction networks, which involve redox signaling with implications in cancer, fibrosis, renal dysfunction, or Alzheimer's disease. Through NADPH oxidase (NOX)-dependent ROS, the extracellular PG, hyaluronan is involved in osteoclastogenesis and cancer. The ROS sources, NOX1 and NOX4, increase biglycan-induced inflammation, while NOX2 is a negative regulator.
Critical Issues:
The complexity of the mechanisms that bring ROS into the light of PG biology might be the foundation of a new research area with significant promise for understanding health and disease. Important aspects need to be investigated in PG/ROS signaling: the discovery of specific targets of ROS, the precise ROS-induced chemical modifications of these targets, and the study of their pathological relevance.
Future Directions:
As we become more and more aware of the interactions between PG and ROS signaling underlying intracellular communication and cell fate decisions, it is quite conceivable that this field will allow to identify new therapeutic targets.—Antioxid. Redox Signal. 27, 855–873.
Get full access to this article
View all access options for this article.
References
1.
AfonsoV, ChampyR, MitrovicD, CollinP, and LomriA. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine, 74: 324–329, 2007.
2.
AfratisN, GialeliC, NikitovicD, TsegenidisT, KarousouE, TheocharisAD, PavaoMS, TzanakakisGN, and KaramanosNK. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J, 279: 1177–1197, 2012.
3.
AfratisNA, NikitovicD, MulthauptHA, TheocharisAD, CouchmanJR, and KaramanosNK. Syndecans—key regulators of cell signaling and biological functions. FEBS J, 284: 27–41, 2017.
4.
AmesBN, ShigenagaMK, and HagenTM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A, 90: 7915–7922, 1993.
5.
AnttilaMA, TammiRH, TammiMI, SyrjanenKJ, SaarikoskiSV, and KosmaVM. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res, 60: 150–155, 2000.
6.
BabelovaA, MorethK, Tsalastra-GreulW, Zeng-BrouwersJ, EickelbergO, YoungMF, BrucknerP, PfeilschifterJ, SchaeferRM, GroneHJ, and SchaeferL. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem, 284: 24035–24048, 2009.
7.
BaghyK, HorvathZ, RegosE, KissK, SchaffZ, IozzoRV, and KovalszkyI. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J, 280: 2150–2164, 2013.
8.
BaghyK, IozzoRV, and KovalszkyI. Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem, 60: 262–268, 2012.
9.
BartolazziA, PeachR, AruffoA, and StamenkovicI. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med, 180: 53–66, 1994.
10.
BedardK and KrauseKH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 87: 245–313, 2007.
11.
BernfieldM, GotteM, ParkPW, ReizesO, FitzgeraldML, LincecumJ, and ZakoM. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem, 68: 729–777, 1999.
12.
BlockK, GorinY, and AbboudHE. Subcellular localization of Nox4 and regulation in diabetes. Proc Natl Acad Sci U S A, 106: 14385–14390, 2009.
13.
BlockK, GorinY, NewDD, EidA, ChelmickiT, ReedA, ChoudhuryGG, ParekhDJ, and AbboudHE. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol, 176: 2447–2455, 2010.
14.
BourguignonLY, GiladE, PeyrollierK, BrightmanA, and SwansonRA. Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes. J Neurochem, 101: 1002–1017, 2007.
15.
BoweMA, MendisDB, and FallonJR. The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. J Cell Biol, 148: 801–810, 2000.
16.
BrandanE, RetamalC, Cabello-VerrugioC, and MarzoloMP. The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. J Biol Chem, 281: 31562–31571, 2006.
17.
BrozP and DixitVM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol, 16: 407–420, 2016.
18.
BryantCE, GayNJ, HeymansS, SacreS, SchaeferL, and MidwoodKS. Advances in Toll-like receptor biology: modes of activation by diverse stimuli. Crit Rev Biochem Mol Biol, 50: 359–379, 2015.
19.
BuraschiS, NeillT, GoyalA, PoluzziC, SmythiesJ, OwensRT, SchaeferL, TorresA, and IozzoRV. Decorin causes autophagy in endothelial cells via Peg3. Proc Natl Acad Sci U S A, 110: E2582-E2591, 2013.
20.
CampoGM, AvenosoA, D'AscolaA, ScuruchiM, PrestipinoV, NastasiG, CalatroniA, and CampoS. The inhibition of hyaluronan degradation reduced pro-inflammatory cytokines in mouse synovial fibroblasts subjected to collagen-induced arthritis. J Cell Biochem, 113: 1852–1867, 2012.
21.
CarlstromM, BrownRD, SallstromJ, LarssonE, ZilmerM, ZabihiS, ErikssonUJ, and PerssonAE. SOD1 deficiency causes salt sensitivity and aggravates hypertension in hydronephrosis. Am J Physiol Regul Integr Comp Physiol, 297: R82–R92, 2009.
22.
Casalino-MatsudaSM, MonzonME, ConnerGE, SalatheM, and FortezaRM. Role of hyaluronan and reactive oxygen species in tissue kallikrein-mediated epidermal growth factor receptor activation in human airways. J Biol Chem, 279: 21606–21616, 2004.
23.
Casalino-MatsudaSM, MonzonME, DayAJ, and FortezaRM. Hyaluronan fragments/CD44 mediate oxidative stress-induced MUC5B up-regulation in airway epithelium. Am J Respir Cell Mol Biol, 40: 277–285, 2009.
24.
ChandelNS and TuvesonDA. The promise and perils of antioxidants for cancer patients. N Engl J Med, 371: 177–178, 2014.
ChenE, HermansonS, and EkkerSC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood, 103: 1710–1719, 2004.
27.
ChenXD, FisherLW, RobeyPG, and YoungMF. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J, 18: 948–958, 2004.
28.
ChengB, MontmassonM, TerradotL, and RousselleP. Syndecans as cell surface receptors in cancer biology. A focus on their interaction with PDZ domain proteins. Front Pharmacol, 7: 10, 2016.
29.
ChengY and LiG. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev, 31: 75–87, 2012.
30.
ChungH, MulthauptHA, OhES, and CouchmanJR. Minireview: syndecans and their crucial roles during tissue regeneration. FEBS Lett, 590: 2408–2417, 2016.
CouchmanJR, MulthauptH, and SandersonRD. Recent insights into cell surface heparan sulphate proteoglycans and cancer. F1000Res, 5: 1541, 2016.
33.
D'AutreauxB and ToledanoMB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol, 8: 813–824, 2007.
34.
da SilvaEZ, JamurMC, and OliverC. Mast cell function: a new vision of an old cell. J Histochem Cytochem, 62: 698–738, 2014.
35.
DekkerLV, LeitgesM, AltschulerG, MistryN, McDermottA, RoesJ, and SegalAW. Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. Biochem J, 347Pt 1: 285–289, 2000.
36.
DesnoyersL, ArnottD, and PennicaD. WISP-1 binds to decorin and biglycan. J Biol Chem, 276: 47599–47607, 2001.
37.
DieboldI, FlugelD, BechtS, BelaibaRS, BonelloS, HessJ, KietzmannT, and GorlachA. The hypoxia-inducible factor-2alpha is stabilized by oxidative stress involving NOX4. Antioxid Redox Signal, 13: 425–436, 2010.
38.
DiehnM, ChoRW, LoboNA, KaliskyT, DorieMJ, KulpAN, QianD, LamJS, AillesLE, WongM, JoshuaB, KaplanMJ, WapnirI, DirbasFM, SomloG, GarberoglioC, PazB, ShenJ, LauSK, QuakeSR, BrownJM, WeissmanIL, and ClarkeMF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458: 780–783, 2009.
39.
DixonSJ and StockwellBR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol, 10: 9–17, 2014.
40.
DrummondGR, SelemidisS, GriendlingKK, and SobeyCG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov, 10: 453–471, 2011.
41.
DuchezS, PascalV, CogneN, Jayat-VignolesC, JulienR, and CogneM. Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B-cell development and activation. Eur J Immunol, 41: 3632–3644, 2011.
42.
EnghildJJ, ThogersenIB, OuryTD, ValnickovaZ, HojrupP, and CrapoJD. The heparin-binding domain of extracellular superoxide dismutase is proteolytically processed intracellularly during biosynthesis. J Biol Chem, 274: 14818–14822, 1999.
43.
FattmanCL, SchaeferLM, and OuryTD. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med, 35: 236–256, 2003.
FreyH, MorethK, HsiehLT-H, Zeng-BrouwersJ, RathkolbB, FuchsH, Gailus-DurnerV, IozzoRV, de AngelisMH, and SchaeferL. A novel biological function of soluble biglycan: induction of erythropoietin production and polycythemia. Glycoconj J, 34: 393–404, 2017.
46.
FreyH, SchroederN, Manon-JensenT, IozzoRV, and SchaeferL. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J, 280: 2165–2179, 2013.
47.
FrikecheJ, MaitiG, and ChakravartiS. Small leucine-rich repeat proteoglycans in corneal inflammation and wound healing. Exp Eye Res, 151: 142–149, 2016.
48.
GaoQ, LuJ, HuoY, BabyN, LingEA, and DheenST. NG2, a member of chondroitin sulfate proteoglycans family mediates the inflammatory response of activated microglia. Neuroscience, 165: 386–394, 2010.
GoldoniS, HumphriesA, NystromA, SattarS, OwensRT, McQuillanDJ, IretonK, and IozzoRV. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol, 185: 743–754, 2009.
51.
GrothS, SchulzeM, KalthoffH, FandrichF, and UngefrorenH. Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J Biol Chem, 280: 33190–33199, 2005.
52.
GubbiottiMA and IozzoRV. Proteoglycans regulate autophagy via outside-in signaling: an emerging new concept. Matrix Biol, 48: 6–13, 2015.
53.
GubbiottiMA, NeillT, FreyH, SchaeferL, and IozzoRV. Decorin is an autophagy-inducible proteoglycan and is required for proper in vivo autophagy. Matrix Biol, 48: 14–25, 2015.
54.
GubbiottiMA, ValletSD, Ricard-BlumS, and IozzoRV. Decorin interacting network: a comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol, 55: 7–21, 2016.
55.
HamiltonSR, FardSF, PaiwandFF, TolgC, VeisehM, WangC, McCarthyJB, BissellMJ, KoropatnickJ, and TurleyEA. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem, 282: 16667–16680, 2007.
56.
HascallVC, MajorsAK, De La MotteCA, EvankoSP, WangA, DrazbaJA, StrongSA, and WightTN. Intracellular hyaluronan: a new frontier for inflammation?. Biochim Biophys Acta, 1673: 3–12, 2004.
57.
HeldinP. Importance of hyaluronan biosynthesis and degradation in cell differentiation and tumor formation. Braz J Med Biol Res, 36: 967–973, 2003.
58.
HenrotinYE, BrucknerP, and PujolJP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage, 11: 747–755, 2003.
59.
HildebrandA, RomarisM, RasmussenLM, HeinegardD, TwardzikDR, BorderWA, and RuoslahtiE. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J, 302 (Pt 2): 527–534, 1994.
60.
HordijkPL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res, 98: 453–462, 2006.
61.
HsiehLT, FreyH, NastaseMV, TredupC, HoffmannA, PoluzziC, Zeng-BrouwersJ, Manon-JensenT, SchroderK, BrandesRP, IozzoRV, and SchaeferL. Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1beta synthesis. Matrix Biol, 49: 61–81, 2016.
62.
HsiehLT, NastaseMV, RoedigH, Zeng-BrouwersJ, PoluzziC, SchwalmS, ForkC, TredupC, BrandesRP, WygreckaM, HuwilerA, PfeilschifterJ, and SchaeferL. Biglycan- and sphingosine kinase-1 signaling crosstalk regulates the synthesis of macrophage chemoattractants. Int J Mol Sci, 18: E595, 2017.
63.
HsiehLT, NastaseMV, Zeng-BrouwersJ, IozzoRV, and SchaeferL. Soluble biglycan as a biomarker of inflammatory renal diseases. Int J Biochem Cell Biol, 54: 223–235, 2014.
64.
HumphriesDE, NicodemusCF, SchillerV, and StevensRL. The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells. J Biol Chem, 267: 13558–13563, 1992.
65.
IovineB, NinoM, IraceC, BevilacquaMA, and MonfrecolaG. Ultraviolet B and A irradiation induces fibromodulin expression in human fibroblasts in vitro. Biochimie, 91: 364–372, 2009.
66.
IozzoRV, MoscatelloDK, McQuillanDJ, and EichstetterI. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem, 274: 4489–4492, 1999.
67.
IozzoRV and MurdochAD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J, 10: 598–614, 1996.
68.
IozzoRV and SchaeferL. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J, 277: 3864–3875, 2010.
69.
IozzoRV and SchaeferL. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol, 42: 11–55, 2015.
70.
IshimotoT, NaganoO, YaeT, TamadaM, MotoharaT, OshimaH, OshimaM, IkedaT, AsabaR, YagiH, MasukoT, ShimizuT, IshikawaT, KaiK, TakahashiE, ImamuraY, BabaY, OhmuraM, SuematsuM, BabaH, and SayaH. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell, 19: 387–400, 2011.
71.
JiangD, LiangJ, FanJ, YuS, ChenS, LuoY, PrestwichGD, MascarenhasMM, GargHG, QuinnDA, HomerRJ, GoldsteinDR, BucalaR, LeePJ, MedzhitovR, and NoblePW. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med, 11: 1173–1179, 2005.
72.
JiangD, LiangJ, and NoblePW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol, 23: 435–461, 2007.
73.
JiangD, LiangJ, and NoblePW. Hyaluronan as an immune regulator in human diseases. Physiol Rev, 91: 221–264, 2011.
74.
KarousouE, MisraS, GhatakS, DobraK, GotteM, VigettiD, PassiA, KaramanosNK, and SkandalisSS. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol, 59: 3–22, 2016.
75.
KimBT, KitagawaH, TamuraJ, SaitoT, Kusche-GullbergM, LindahlU, and SugaharaK. Human tumor suppressor EXT gene family members EXTL1 and EXTL3 encode alpha 1,4- N-acetylglucosaminyltransferases that likely are involved in heparan sulfate/heparin biosynthesis. Proc Natl Acad Sci U S A, 98: 7176–7181, 2001.
76.
KimEY, RoshanravanH, and DryerSE. Syndecan-4 ectodomain evokes mobilization of podocyte TRPC6 channels and their associated pathways: an essential role for integrin signaling. Biochim Biophys Acta, 1853: 2610–2620, 2015.
77.
KimJ, LeeJH, ParkHS, HwangJ, HanIO, BaeYS, and OhES. Syndecan-4 regulates platelet-derived growth factor-mediated MAP kinase activation by altering intracellular reactive oxygen species. FEBS Lett, 582: 2725–2730, 2008.
78.
KimY, LeeYS, ChoeJ, LeeH, KimYM, and JeoungD. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem, 283: 22513–22528, 2008.
79.
KimYJ, GoH, WuHG, JeonYK, ParkSW, and LeeSH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck, 33: 1458–1466, 2011.
80.
KolsetSO and PejlerG. Serglycin: a structural and functional chameleon with wide impact on immune cells. J Immunol, 187: 4927–4933, 2011.
81.
KolsetSO and TveitH. Serglycin—structure and biology. Cell Mol Life Sci, 65: 1073–1085, 2008.
82.
KorpetinouA, SkandalisSS, LabropoulouVT, SmirlakiG, NoulasA, KaramanosNK, and TheocharisAD. Serglycin: at the crossroad of inflammation and malignancy. Front Oncol, 3: 327, 2014.
83.
KouvidiK, BerdiakiA, NikitovicD, KatonisP, AfratisN, HascallVC, KaramanosNK, and TzanakakisGN. Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem, 286: 38509–38520, 2011.
84.
KunisadaM, YogiantiF, SakumiK, OnoR, NakabeppuY, and NishigoriC. Increased expression of versican in the inflammatory response to UVB- and reactive oxygen species-induced skin tumorigenesis. Am J Pathol, 179: 3056–3065, 2011.
85.
KwonMJ, JangB, YiJY, HanIO, and OhES. Syndecans play dual roles as cell adhesion receptors and docking receptors. FEBS Lett, 586: 2207–2211, 2012.
86.
LambaertsK, Wilcox-AdelmanSA, and ZimmermannP. The signaling mechanisms of syndecan heparan sulfate proteoglycans. Curr Opin Cell Biol, 21: 662–669, 2009.
87.
LambethJD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol, 4: 181–189, 2004.
LeeJY and SpicerAP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol, 12: 581–586, 2000.
90.
LeitchJM, YickPJ, and CulottaVC. The right to choose: multiple pathways for activating copper, zinc superoxide dismutase. J Biol Chem, 284: 24679–24683, 2009.
91.
LendorfME, Manon-JensenT, KronqvistP, MulthauptHA, and CouchmanJR. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem, 59: 615–629, 2011.
92.
LennonFE and SingletonPA. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis, 1: 200–213, 2011.
93.
LiX, RoifeD, KangY, DaiB, PrattM, and FlemingJB. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Oncogene, 35: 4881–4890, 2016.
94.
LimST, LongleyRL, CouchmanJR, and WoodsA. Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase C alpha (PKC alpha) increases focal adhesion localization of PKC alpha. J Biol Chem, 278: 13795–13802, 2003.
95.
LinCW, LuKY, WangSY, SungHW, and MiFL. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release. Acta Biomater, 35: 280–292, 2016.
96.
LiochevSI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med, 60: 1–4, 2013.
97.
LiuY, EchtermeyerF, ThiloF, TheilmeierG, SchmidtA, SchuleinR, JensenBL, LoddenkemperC, JankowskiV, MarcussenN, GollaschM, ArendshorstWJ, and TepelM. The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via RhoA/Rho-associated protein kinase signaling. Arterioscler Thromb Vasc Biol, 32: 378–385, 2012.
98.
LoM, WangYZ, and GoutPW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol, 215: 593–602, 2008.
99.
LohrK, SardanaH, LeeS, WuF, HusoDL, HamadAR, and ChakravartiS. Extracellular matrix protein lumican regulates inflammation in a mouse model of colitis. Inflamm Bowel Dis, 18: 143–151, 2012.
100.
LyleAN, DeshpandeNN, TaniyamaY, Seidel-RogolB, PounkovaL, DuP, PapaharalambusC, LassegueB, and GriendlingKK. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res, 105: 249–259, 2009.
101.
MahalingamY, GallagherJT, and CouchmanJR. Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties. J Biol Chem, 282: 3221–3230, 2007.
102.
MarklundSL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A, 79: 7634–7638, 1982.
103.
MarshallLJ, RamdinLS, BrooksT, PCDP, and ShuteJK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol, 171: 2057–2065, 2003.
104.
MausF, SakryD, BinameF, KarramK, RajalingamK, WattsC, HeywoodR, KrugerR, StegmullerJ, WernerHB, NaveKA, Kramer-AlbersEM, and TrotterJ. The NG2 proteoglycan protects oligodendrocyte precursor cells against oxidative stress via interaction with OMI/HtrA2. PLoS One, 10: e0137311, 2015.
105.
MaytinEV. Hyaluronan: more than just a wrinkle filler. Glycobiology, 26: 553–559, 2016.
MerlineR, MorethK, BeckmannJ, NastaseMV, Zeng-BrouwersJ, TralhaoJG, LemarchandP, PfeilschifterJ, SchaeferRM, IozzoRV, and SchaeferL. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal, 4: ra75, 2011.
108.
MerlineR, SchaeferRM, and SchaeferL. The matricellular functions of small leucine-rich proteoglycans (SLRPs). J Cell Commun Signal, 3: 323–335, 2009.
109.
MisraS, HeldinP, HascallVC, KaramanosNK, SkandalisSS, MarkwaldRR, and GhatakS. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J, 278: 1429–1443, 2011.
110.
MizumotoS, YamadaS, and SugaharaK. Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins. Curr Opin Struct Biol, 34: 35–42, 2015.
111.
MochidaY, ParisuthimanD, and YamauchiM. Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation. Adv Exp Med Biol, 585: 101–113, 2006.
112.
MonslowJ, GovindarajuP, and PureE. Hyaluronan—a functional and structural sweet spot in the tissue microenvironment. Front Immunol, 6: 231, 2015.
113.
MorethK, BrodbeckR, BabelovaA, GretzN, SpiekerT, Zeng-BrouwersJ, PfeilschifterJ, YoungMF, SchaeferRM, and SchaeferL. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest, 120: 4251–4272, 2010.
114.
MorethK, FreyH, HuboM, Zeng-BrouwersJ, NastaseMV, HsiehLT, HaceniR, PfeilschifterJ, IozzoRV, and SchaeferL. Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol, 35: 143–151, 2014.
115.
MorethK, IozzoRV, and SchaeferL. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle, 11: 2084–2091, 2012.
116.
MormoneE, LuY, GeX, FielMI, and NietoN. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. Gastroenterology, 142: 612–621 e5, 2012.
117.
MouwJK, OuG, and WeaverVM. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol, 15: 771–785, 2014.
MuscoliC, CuzzocreaS, RileyDP, ZweierJL, ThiemermannC, WangZQ, and SalveminiD. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol, 140: 445–460, 2003.
120.
NaorD, NedvetzkiS, GolanI, MelnikL, and FaitelsonY. CD44 in cancer. Crit Rev Clin Lab Sci, 39: 527–579, 2002.
121.
NastaseMV, IozzoRV, and SchaeferL. Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim Biophys Acta, 1840: 2460–2470, 2014.
122.
NastaseMV, YoungMF, and SchaeferL. Biglycan: a multivalent proteoglycan providing structure and signals. J Histochem Cytochem, 60: 963–975, 2012.
123.
NathanC. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest, 111: 769–778, 2003.
124.
NayakBK, FeliersD, SudarshanS, FriedrichsWE, DayRT, NewDD, FitzgeraldJP, EidA, DenapoliT, ParekhDJ, GorinY, and BlockK. Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene, 32: 3147–3155, 2013.
125.
NedvetzkiS, GonenE, AssayagN, ReichR, WilliamsRO, ThurmondRL, HuangJF, NeudeckerBA, WangFS, TurleyEA, and NaorD. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A, 101: 18081–18086, 2004.
126.
NeillT, SchaeferL, and IozzoRV. Instructive roles of extracellular matrix on autophagy. Am J Pathol, 184: 2146–2153, 2014.
127.
NeillT, SchaeferL, and IozzoRV. Decoding the matrix: instructive roles of proteoglycan receptors. Biochemistry, 54: 4583–4598, 2015.
128.
NeillT, SchaeferL, and IozzoRV. Oncosuppressive functions of decorin. Mol Cell Oncol, 2: e975645, 2015.
129.
NeillT, SchaeferL, and IozzoRV. Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev, 97: 174–185, 2016.
130.
NoblePW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol, 21: 25–29, 2002.
131.
NogueiraV, ParkY, ChenCC, XuPZ, ChenML, TonicI, UntermanT, and HayN. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell, 14: 458–470, 2008.
132.
NovoE and ParolaM. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair, 1: 5, 2008.
133.
PanD. The hippo signaling pathway in development and cancer. Dev Cell, 19: 491–505, 2010.
134.
PandayA, SahooMK, OsorioD, and BatraS. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol, 12: 5–23, 2015.
135.
ParishCR. The role of heparan sulphate in inflammation. Nat Rev Immunol, 6: 633–643, 2006.
136.
PiperigkouZ, MohrB, KaramanosN, and GotteM. Shed proteoglycans in tumor stroma. Cell Tissue Res, 365: 643–655, 2016.
137.
PontaH, ShermanL, and HerrlichPA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol, 4: 33–45, 2003.
138.
PorschH, BernertB, MehicM, TheocharisAD, HeldinCH, and HeldinP. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene, 32: 4355–4365, 2013.
139.
PrassasI, EissaA, PodaG, and DiamandisEP. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov, 14: 183–202, 2015.
140.
PrehmP. Hyaluronate is synthesized at plasma membranes. Biochem J, 220: 597–600, 1984.
141.
RamnathR, FosterRR, QiuY, CopeG, ButlerMJ, SalmonAH, MathiesonPW, CowardRJ, WelshGI, and SatchellSC. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha: a contributor to endothelial cell glycocalyx dysfunction. FASEB J, 28: 4686–4699, 2014.
RieberN, HectorA, KuijpersT, RoosD, and HartlD. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol, 2012: 252460, 2012.
RyuHY, LeeJ, YangS, ParkH, ChoiS, JungKC, LeeST, SeongJK, HanIO, and OhES. Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem, 284: 35692–35701, 2009.
146.
SabharwalSS and SchumackerPT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat Rev Cancer, 14: 709–721, 2014.
147.
SacksJD and BarbolinaMV. Expression and function of CD44 in epithelial ovarian carcinoma. Biomolecules, 5: 3051–3066, 2015.
148.
SakaiK, KimataK, SatoT, GotohM, NarimatsuH, ShinomiyaK, and WatanabeH. Chondroitin sulfate N-acetylgalactosaminyltransferase-1 plays a critical role in chondroitin sulfate synthesis in cartilage. J Biol Chem, 282: 4152–4161, 2007.
149.
SampsonN, KozielR, ZenzmaierC, BubendorfL, PlasE, Jansen-DurrP, and BergerP. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol, 25: 503–515, 2011.
150.
SatoH, TakahashiT, IdeH, FukushimaT, TabataM, SekineF, KobayashiK, NegishiM, and NiwaY. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. Arthritis Rheum, 31: 63–71, 1988.
151.
SchaeferL. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr Opin Pharmacol, 10: 185–190, 2010.
152.
SchaeferL. Small leucine-rich proteoglycans in kidney disease. J Am Soc Nephrol, 22: 1200–1207, 2011.
153.
SchaeferL. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem, 289: 35237–35245, 2014.
154.
SchaeferL, BabelovaA, KissE, HausserHJ, BaliovaM, KrzyzankovaM, MarscheG, YoungMF, MihalikD, GotteM, MalleE, SchaeferRM, and GroneHJ. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest, 115: 2223–2233, 2005.
155.
SchaeferL, BeckKF, RaslikI, WalpenS, MihalikD, MicegovaM, MacakovaK, SchonherrE, SeidlerDG, VargaG, SchaeferRM, KresseH, and PfeilschifterJ. Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells. J Biol Chem, 278: 26227–26237, 2003.
156.
SchaeferL, GroneHJ, RaslikI, RobenekH, UgorcakovaJ, BudnyS, SchaeferRM, and KresseH. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. Kidney Int, 58: 1557–1568, 2000.
157.
SchaeferL and IozzoRV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem, 283: 21305–21309, 2008.
158.
SchaeferL, MacakovaK, RaslikI, MicegovaM, GroneHJ, SchonherrE, RobenekH, EchtermeyerFG, GrasselS, BrucknerP, SchaeferRM, IozzoRV, and KresseH. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol, 160: 1181–1191, 2002.
159.
SchaeferL and SchaeferRM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res, 339: 237–246, 2010.
160.
SchaeferL, TredupC, GubbiottiMA, and IozzoRV. Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. FEBS J, 284: 10–26, 2017.
161.
SchaeferL, TsalastraW, BabelovaA, BaliovaM, MinnerupJ, SorokinL, GroneHJ, ReinhardtDP, PfeilschifterJ, IozzoRV, and SchaeferRM. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. Am J Pathol, 170: 301–315, 2007.
162.
SchappiMG, JaquetV, BelliDC, and KrauseKH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol, 30: 255–271, 2008.
163.
SchenckP, SchneiderS, MiehlkeR, and PrehmP. Synthesis and degradation of hyaluronate by synovia from patients with rheumatoid arthritis. J Rheumatol, 22: 400–405, 1995.
164.
SchickBP. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog Mol Biol Transl Sci, 93: 235–287, 2010.
165.
SegalBH, HanW, BusheyJJ, JooM, BhattiZ, FeminellaJ, DennisCG, VethanayagamRR, YullFE, CapitanoM, WallacePK, MindermanH, ChristmanJW, SpornMB, ChanJ, VinhDC, HollandSM, RomaniLR, GaffenSL, FreemanML, and BlackwellTS. NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One, 5: e9631, 2010.
166.
ShimadaK, AnaiS, FujiiT, TanakaN, FujimotoK, and KonishiN. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol, 231: 495–504, 2013.
167.
ShimadaK, NakamuraM, De VelascoMA, TanakaM, OujiY, and KonishiN. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci, 100: 1248–1254, 2009.
168.
ShimadaK, NakamuraM, De VelascoMA, TanakaM, OujiY, MiyakeM, FujimotoK, HiraoK, and KonishiN. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci, 101: 155–160, 2010.
169.
SklirisA, HapponenKE, TerposE, LabropoulouV, BorsetM, HeinegardD, BlomAM, and TheocharisAD. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol, 41: 437–449, 2011.
170.
SklirisA, LabropoulouVT, PapachristouDJ, AletrasA, KaramanosNK, and TheocharisAD. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases. FEBS J, 280: 2342–2352, 2013.
171.
SoltesL, MendichiR, KoganG, SchillerJ, StankovskaM, and ArnholdJ. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules, 7: 659–668, 2006.
172.
SpinelliFM, VitaleDL, DemarchiG, CristinaC, and AlanizL. The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunology, 4: e52, 2015.
173.
StantonH, MelroseJ, LittleCB, and FosangAJ. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta, 1812: 1616–1629, 2011.
174.
SzatrowskiTP and NathanCF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res, 51: 794–798, 1991.
175.
TermeerC, BenedixF, SleemanJ, FieberC, VoithU, AhrensT, MiyakeK, FreudenbergM, GalanosC, and SimonJC. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med, 195: 99–111, 2002.
176.
TheocharisAD, SkandalisSS, TzanakakisGN, and KaramanosNK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J, 277: 3904–3923, 2010.
177.
ThiloF, LeeM, XiaS, ZakrzewiczA, and TepelM. High glucose modifies transient receptor potential canonical type 6 channels via increased oxidative stress and syndecan-4 in human podocytes. Biochem Biophys Res Commun, 450: 312–317, 2014.
178.
TikuML, GuptaS, and DeshmukhDR. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Radic Res, 30: 395–405, 1999.
179.
TooleBP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer, 4: 528–539, 2004.
180.
TorresA, GubbiottiMA, and IozzoRV. Decorin-inducible Peg3 evokes beclin 1-mediated autophagy and thrombospondin 1-mediated angiostasis. J Biol Chem, 292: 5055–5069, 2017.
181.
Toyama-SorimachiN, SorimachiH, TobitaY, KitamuraF, YagitaH, SuzukiK, and MiyasakaM. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem, 270: 7437–7444, 1995.
182.
TrachoothamD, ZhouY, ZhangH, DemizuY, ChenZ, PelicanoH, ChiaoPJ, AchantaG, ArlinghausRB, LiuJ, and HuangP. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell, 10: 241–252, 2006.
183.
TufvessonE and Westergren-ThorssonG. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS Lett, 530: 124–128, 2002.
184.
Vande WalleL, LamkanfiM, and VandenabeeleP. The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ, 15: 453–460, 2008.
185.
ViolaM, VigettiD, KarousouE, D'AngeloML, CaonI, MorettoP, De LucaG, and PassiA. Biology and biotechnology of hyaluronan. Glycoconj J, 32: 93–103, 2015.
186.
WeissmannB, MeyerK, SampsonP, and LinkerA. Isolation of oligosaccharides enzymatically produced from hyaluronic acid. J Biol Chem, 208: 417–429, 1954.
187.
WoodsA, LongleyRL, TumovaS, and CouchmanJR. Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch Biochem Biophys, 374: 66–72, 2000.
188.
WoulfeDS, LilliendahlJK, AugustS, RauovaL, KowalskaMA, AbrinkM, PejlerG, WhiteJG, and SchickBP. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood, 111: 3458–3467, 2008.
189.
WuF, VijN, RobertsL, Lopez-BrionesS, JoyceS, and ChakravartiS. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem, 282: 26409–26417, 2007.
WuthrichRP. The proinflammatory role of hyaluronan-CD44 interactions in renal injury. Nephrol Dial Transplant, 14: 2554–2556, 1999.
192.
XianX, GopalS, and CouchmanJR. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res, 339: 31–46, 2010.
193.
XuY, StamenkovicI, and YuQ. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res, 70: 2455–2464, 2010.
194.
YamasakiK, MutoJ, TaylorKR, CogenAL, AudishD, BertinJ, GrantEP, CoyleAJ, MisaghiA, HoffmanHM, and GalloRL. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem, 284: 12762–12771, 2009.
195.
YoshidaGJ and SayaH. Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun, 443: 622–627, 2014.
196.
YuH, LiQ, ZhouX, KolosovVP, and PerelmanJM. Role of hyaluronan and CD44 in reactive oxygen species-induced mucus hypersecretion. Mol Cell Biochem, 352: 65–75, 2011.
Zeng-BrouwersJ, BeckmannJ, NastaseMV, IozzoRV, and SchaeferL. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. Matrix Biol, 35: 132–142, 2014.
199.
ZhaQB, WeiHX, LiCG, LiangYD, XuLH, BaiWJ, PanH, HeXH, and OuyangDY. ATP-induced inflammasome activation and pyroptosis is regulated by AMP-activated protein kinase in macrophages. Front Immunol, 7: 597, 2016.
